ALGOS PHARMACEUTICAL CORP
SC 13G/A, 1999-02-16
PHARMACEUTICAL PREPARATIONS
Previous: ALGOS PHARMACEUTICAL CORP, SC 13G/A, 1999-02-16
Next: ALGOS PHARMACEUTICAL CORP, SC 13G/A, 1999-02-16







<PAGE>

<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON D.C. 20549

                                 SCHEDULE 13G/A
                                 (RULE 13D-102)
             INFORMATION STATEMENT PURSUANT TO RULES 13D-1 AND 13D-2
                    UNDER THE SECURITIES EXCHANGE ACT OF 1934

                        ALGOS PHARMACEUTICAL CORPORATION
                                (NAME OF ISSUER)

                     COMMON STOCK, PAR VALUE $.01 PER SHARE
                         (TITLE OF CLASS OF SECURITIES)

                                   015869 10 0
                                 (CUSIP NUMBER)


                               Page 1 of 5 pages




<PAGE>

<PAGE>


                                      13G/A

CUSIP NO. 015869 10 0
      ---------------

1.   NAME OF REPORTING PERSON:
     KAREN LYLE                                                  
     ------------------------------------------------------------------------

2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

                                                                       (A) [ ]
                                                                       (B) [ ]

3.   SEC USE ONLY

4.   CITIZENSHIP OR PLACE OF ORGANIZATION:
     UNITED STATES CITIZEN                                       

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

5.   SOLE VOTING POWER:

                              1,774,354

6.   SHARED VOTING POWER:

                              -0-

7.   SOLE DISPOSITIVE POWER:

                              1,774,354

8.   SHARED DISPOSITIVE POWER:

                              -0-

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

                              1,774,354

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

                              [ ]

11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9:
                                                       10.2%

12.  TYPE OF REPORTING PERSON:

                               IN


                               Page 2 of 5 pages




<PAGE>

<PAGE>




ITEM 1.
     (a)  Name of Issuer: Algos Pharmaceutical Corporation
     (b)  Address of Issuer's Principal Executive Offices:
               1333 Campus Parkway
               Neptune, New Jersey 07753

ITEM 2.
     (a)  Name of Person Filing:      Karen Lyle
     (b)  Address of Principal Business Office:
               Algos Pharmaceutical Corporation
               1333 Campus Parkway
               Neptune, New Jersey 07753
     (c)  Citizenship: United States
     (d) Title of Class of Securities:
               Common Stock, $.01 par value
     (e)  CUSIP Number: 015869 10 0


ITEM 3. Not applicable.

ITEM 4. OWNERSHIP
     (a)  Amount Beneficially Owned: 1,774,354
     (b)  Percent of Class: 10.2%
     (c) Number of shares as to which such person has:
          (i)   sole power to vote or to direct the vote:

                           1,774,354                             

          (ii)  shared power to vote or to direct the vote:

                           -0-                                   

          (iii) sole power to dispose or to direct the disposition of:

                           1,774,354                             

          (iv) shared power to dispose or to direct the disposition of:

                          -0-                                    

                               Page 3 of 5 pages



<PAGE>

<PAGE>

ITEM 5.   OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

          Not applicable.

ITEM 6.   OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF
          ANOTHER PERSON:

          The 1,774,354 shares reported by Mrs. Lyle, includes 74,700 shares of
          common stock and options to purchase 343,700 shares owned directly by
          John W. Lyle, husband of Mrs. Lyle, and 38 shares owned directly by
          Mrs. Lyle's son, as to which Mrs. Lyle disclaims beneficial ownership.

ITEM 7.   IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY
          WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE
          PARENT HOLDING COMPANY:

          Not applicable.

ITEM 8.   IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

          Not applicable.

ITEM 9.   NOTICE OF DISSOLUTION OF GROUP:

          Not applicable.

ITEM 10.  CERTIFICATION:

          Not applicable.

                               Page 4 of 5 pages




<PAGE>

<PAGE>


                                    SIGNATURE

          After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.

          Date: February 4, 1999

                                            /s/ Karen Lyle
                                                ----------------------
                                                Karen Lyle



                                Page 5 of 5 pages



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission